Does bilateral stimulation of the subthalamic nucleus aggravate apathy in Parkinson's disease?
Identifieur interne : 000F47 ( PubMed/Corpus ); précédent : 000F46; suivant : 000F48Does bilateral stimulation of the subthalamic nucleus aggravate apathy in Parkinson's disease?
Auteurs : V. Czernecki ; B. Pillon ; J L Houeto ; M L Welter ; V. Mesnage ; Y. Agid ; B. DuboisSource :
- Journal of neurology, neurosurgery, and psychiatry [ 0022-3050 ] ; 2005.
English descriptors
- KwdEn :
- Antiparkinson Agents (therapeutic use), Deep Brain Stimulation (adverse effects), Deep Brain Stimulation (instrumentation), Deep Brain Stimulation (statistics & numerical data), Extinction, Psychological, Female, Functional Laterality (physiology), Humans, Levodopa (therapeutic use), Male, Middle Aged, Mood Disorders (diagnosis), Mood Disorders (economics), Mood Disorders (epidemiology), Motivation, Neurosurgical Procedures, Parkinson Disease (epidemiology), Parkinson Disease (surgery), Parkinson Disease (therapy), Reward, Severity of Illness Index, Subthalamic Nucleus (physiology), Subthalamic Nucleus (surgery).
- MESH :
- chemical , therapeutic use : Antiparkinson Agents, Levodopa.
- adverse effects : Deep Brain Stimulation.
- diagnosis : Mood Disorders.
- economics : Mood Disorders.
- epidemiology : Mood Disorders, Parkinson Disease.
- instrumentation : Deep Brain Stimulation.
- physiology : Functional Laterality, Subthalamic Nucleus.
- statistics & numerical data : Deep Brain Stimulation.
- surgery : Parkinson Disease, Subthalamic Nucleus.
- therapy : Parkinson Disease.
- Extinction, Psychological, Female, Humans, Male, Middle Aged, Motivation, Neurosurgical Procedures, Reward, Severity of Illness Index.
Abstract
High frequency stimulation of the subthalamic nucleus (STN) dramatically decreases motor disability in patients with Parkinson"s disease (PD), but has been reported to aggravate apathy. The aim of this study was to analyse the effect of STN stimulation on motivation and reward sensitivity in a consecutive series of PD patients.
DOI: 10.1136/jnnp.2003.033258
PubMed: 15897497
Links to Exploration step
pubmed:15897497Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Does bilateral stimulation of the subthalamic nucleus aggravate apathy in Parkinson's disease?</title><author><name sortKey="Czernecki, V" sort="Czernecki, V" uniqKey="Czernecki V" first="V" last="Czernecki">V. Czernecki</name><affiliation><nlm:affiliation>INSERM U 610, Pavillon Claude Bernard, Hôpital de la Salpêtrière, 47 Boulevard de l'Hôpital, 75651 Paris cedex 13, France. vczernecki@hotmail.com</nlm:affiliation></affiliation></author><author><name sortKey="Pillon, B" sort="Pillon, B" uniqKey="Pillon B" first="B" last="Pillon">B. Pillon</name></author><author><name sortKey="Houeto, J L" sort="Houeto, J L" uniqKey="Houeto J" first="J L" last="Houeto">J L Houeto</name></author><author><name sortKey="Welter, M L" sort="Welter, M L" uniqKey="Welter M" first="M L" last="Welter">M L Welter</name></author><author><name sortKey="Mesnage, V" sort="Mesnage, V" uniqKey="Mesnage V" first="V" last="Mesnage">V. Mesnage</name></author><author><name sortKey="Agid, Y" sort="Agid, Y" uniqKey="Agid Y" first="Y" last="Agid">Y. Agid</name></author><author><name sortKey="Dubois, B" sort="Dubois, B" uniqKey="Dubois B" first="B" last="Dubois">B. Dubois</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2005">2005</date><idno type="RBID">pubmed:15897497</idno><idno type="pmid">15897497</idno><idno type="doi">10.1136/jnnp.2003.033258</idno><idno type="wicri:Area/PubMed/Corpus">000F47</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000F47</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Does bilateral stimulation of the subthalamic nucleus aggravate apathy in Parkinson's disease?</title><author><name sortKey="Czernecki, V" sort="Czernecki, V" uniqKey="Czernecki V" first="V" last="Czernecki">V. Czernecki</name><affiliation><nlm:affiliation>INSERM U 610, Pavillon Claude Bernard, Hôpital de la Salpêtrière, 47 Boulevard de l'Hôpital, 75651 Paris cedex 13, France. vczernecki@hotmail.com</nlm:affiliation></affiliation></author><author><name sortKey="Pillon, B" sort="Pillon, B" uniqKey="Pillon B" first="B" last="Pillon">B. Pillon</name></author><author><name sortKey="Houeto, J L" sort="Houeto, J L" uniqKey="Houeto J" first="J L" last="Houeto">J L Houeto</name></author><author><name sortKey="Welter, M L" sort="Welter, M L" uniqKey="Welter M" first="M L" last="Welter">M L Welter</name></author><author><name sortKey="Mesnage, V" sort="Mesnage, V" uniqKey="Mesnage V" first="V" last="Mesnage">V. Mesnage</name></author><author><name sortKey="Agid, Y" sort="Agid, Y" uniqKey="Agid Y" first="Y" last="Agid">Y. Agid</name></author><author><name sortKey="Dubois, B" sort="Dubois, B" uniqKey="Dubois B" first="B" last="Dubois">B. Dubois</name></author></analytic><series><title level="j">Journal of neurology, neurosurgery, and psychiatry</title><idno type="ISSN">0022-3050</idno><imprint><date when="2005" type="published">2005</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiparkinson Agents (therapeutic use)</term><term>Deep Brain Stimulation (adverse effects)</term><term>Deep Brain Stimulation (instrumentation)</term><term>Deep Brain Stimulation (statistics & numerical data)</term><term>Extinction, Psychological</term><term>Female</term><term>Functional Laterality (physiology)</term><term>Humans</term><term>Levodopa (therapeutic use)</term><term>Male</term><term>Middle Aged</term><term>Mood Disorders (diagnosis)</term><term>Mood Disorders (economics)</term><term>Mood Disorders (epidemiology)</term><term>Motivation</term><term>Neurosurgical Procedures</term><term>Parkinson Disease (epidemiology)</term><term>Parkinson Disease (surgery)</term><term>Parkinson Disease (therapy)</term><term>Reward</term><term>Severity of Illness Index</term><term>Subthalamic Nucleus (physiology)</term><term>Subthalamic Nucleus (surgery)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Deep Brain Stimulation</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Mood Disorders</term></keywords><keywords scheme="MESH" qualifier="economics" xml:lang="en"><term>Mood Disorders</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Mood Disorders</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="instrumentation" xml:lang="en"><term>Deep Brain Stimulation</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Functional Laterality</term><term>Subthalamic Nucleus</term></keywords><keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Deep Brain Stimulation</term></keywords><keywords scheme="MESH" qualifier="surgery" xml:lang="en"><term>Parkinson Disease</term><term>Subthalamic Nucleus</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Extinction, Psychological</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Motivation</term><term>Neurosurgical Procedures</term><term>Reward</term><term>Severity of Illness Index</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">High frequency stimulation of the subthalamic nucleus (STN) dramatically decreases motor disability in patients with Parkinson"s disease (PD), but has been reported to aggravate apathy. The aim of this study was to analyse the effect of STN stimulation on motivation and reward sensitivity in a consecutive series of PD patients.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15897497</PMID><DateCreated><Year>2005</Year><Month>05</Month><Day>17</Day></DateCreated><DateCompleted><Year>2005</Year><Month>06</Month><Day>30</Day></DateCompleted><DateRevised><Year>2014</Year><Month>06</Month><Day>06</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0022-3050</ISSN><JournalIssue CitedMedium="Print"><Volume>76</Volume><Issue>6</Issue><PubDate><Year>2005</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Journal of neurology, neurosurgery, and psychiatry</Title><ISOAbbreviation>J. Neurol. Neurosurg. Psychiatr.</ISOAbbreviation></Journal><ArticleTitle>Does bilateral stimulation of the subthalamic nucleus aggravate apathy in Parkinson's disease?</ArticleTitle><Pagination><MedlinePgn>775-9</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">High frequency stimulation of the subthalamic nucleus (STN) dramatically decreases motor disability in patients with Parkinson"s disease (PD), but has been reported to aggravate apathy. The aim of this study was to analyse the effect of STN stimulation on motivation and reward sensitivity in a consecutive series of PD patients.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Apathy and reward sensitivity (Apathy Scale, Stimulus-Reward Learning, Reversal, Extinction, and Gambling tasks) were assessed in 18 PD patients treated by bilateral STN stimulation ("on" and "off" conditions) compared with 23 matched patients undergoing long term treatment with levodopa ("on" and "off" conditions).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Apathy decreased under both STN stimulation and levodopa treatment, whereas explicit and implicit stimulus reward learning was unchanged.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Bilateral STN stimulation in PD patients does not necessarily have a negative effect on motivation and reward sensitivity and can even improve apathy provided patients have been appropriately selected for neurosurgery.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Czernecki</LastName><ForeName>V</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>INSERM U 610, Pavillon Claude Bernard, Hôpital de la Salpêtrière, 47 Boulevard de l'Hôpital, 75651 Paris cedex 13, France. vczernecki@hotmail.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pillon</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Houeto</LastName><ForeName>J L</ForeName><Initials>JL</Initials></Author><Author ValidYN="Y"><LastName>Welter</LastName><ForeName>M L</ForeName><Initials>ML</Initials></Author><Author ValidYN="Y"><LastName>Mesnage</LastName><ForeName>V</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Agid</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Dubois</LastName><ForeName>B</ForeName><Initials>B</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Neurol Neurosurg Psychiatry</MedlineTA><NlmUniqueID>2985191R</NlmUniqueID><ISSNLinking>0022-3050</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>46627O600J</RegistryNumber><NameOfSubstance UI="D007980">Levodopa</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Neuropsychologia. 2002;40(13):2257-67</RefSource><PMID Version="1">12417456</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Neurol. 1999 Aug;46(2):217-23</RefSource><PMID Version="1">10443887</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2003 May;18(5):524-30</RefSource><PMID Version="1">12722166</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cortex. 1976 Dec;12(4):313-24</RefSource><PMID Version="1">1009768</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Br J Psychiatry. 1979 Apr;134:382-9</RefSource><PMID Version="1">444788</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurol Neurosurg Psychiatry. 2002 Dec;73(6):636-42</RefSource><PMID Version="1">12438462</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neuropsychologia. 2000;38(5):596-612</RefSource><PMID Version="1">10689037</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cereb Cortex. 2000 Mar;10(3):295-307</RefSource><PMID Version="1">10731224</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Brain Cogn. 2000 Apr;42(3):324-47</RefSource><PMID Version="1">10753483</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurosurg. 2000 Apr;92(4):615-25</RefSource><PMID Version="1">10761650</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Brain. 2000 Jun;123 ( Pt 6):1142-54</RefSource><PMID Version="1">10825353</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 2000 Aug 8;55(3):411-8</RefSource><PMID Version="1">10932277</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Brain. 2000 Oct;123 ( Pt 10):2091-108</RefSource><PMID Version="1">11004126</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2001 Sep;16(5):867-75</RefSource><PMID Version="1">11746616</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurosci. 2002 Jan 15;22(2):592-9</RefSource><PMID Version="1">11784807</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Neuropharmacol. 2001 Nov-Dec;24(6):346-51</RefSource><PMID Version="1">11801810</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Brain. 2002 Mar;125(Pt 3):575-83</RefSource><PMID Version="1">11872614</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2002;17 Suppl 3:S116-22</RefSource><PMID Version="1">11948765</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurol Neurosurg Psychiatry. 2002 Jun;72(6):701-7</RefSource><PMID Version="1">12023409</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Psychiatry Res. 2002 Jun 15;114(2):103-11</RefSource><PMID Version="1">12036510</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Brain. 2002 Sep;125(Pt 9):1995-2004</RefSource><PMID Version="1">12183345</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 2002 Oct 26;360(9342):1302-4</RefSource><PMID Version="1">12414208</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Prog Brain Res. 1990;85:119-46</RefSource><PMID Version="1">2094891</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neuropsychiatry Clin Neurosci. 1992 Spring;4(2):134-9</RefSource><PMID Version="1">1627973</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurol Neurosurg Psychiatry. 1994 Dec;57(12):1518-24</RefSource><PMID Version="1">7798983</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurol Neurosurg Psychiatry. 1995 Feb;58(2):174-9</RefSource><PMID Version="1">7876847</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nature. 1996 Mar 7;380(6569):69-72</RefSource><PMID Version="1">8598908</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Science. 1997 Mar 14;275(5306):1593-9</RefSource><PMID Version="1">9054347</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurosci. 1998 Jan 1;18(1):428-37</RefSource><PMID Version="1">9412519</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 1998 Oct 15;339(16):1105-11</RefSource><PMID Version="1">9770557</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 1999 Apr 12;52(6):1227-9</RefSource><PMID Version="1">10214748</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 1999 May 13;340(19):1476-80</RefSource><PMID Version="1">10320386</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 1999 Jul;14(4):572-84</RefSource><PMID Version="1">10435493</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>J Neurol Neurosurg Psychiatry. 2005 Jun;76(6):759-60</RefSource><PMID Version="1">15897490</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000978" MajorTopicYN="N">Antiparkinson Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D046690" MajorTopicYN="Y">Deep Brain Stimulation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000295" MajorTopicYN="N">instrumentation</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics & numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005108" MajorTopicYN="N">Extinction, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007839" MajorTopicYN="N">Functional Laterality</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007980" MajorTopicYN="N">Levodopa</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019964" MajorTopicYN="N">Mood Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009042" MajorTopicYN="Y">Motivation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019635" MajorTopicYN="N">Neurosurgical Procedures</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012201" MajorTopicYN="N">Reward</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020531" MajorTopicYN="N">Subthalamic Nucleus</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading></MeshHeadingList><OtherID Source="NLM">PMC1739659</OtherID></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>5</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>7</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>5</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15897497</ArticleId><ArticleId IdType="pii">76/6/775</ArticleId><ArticleId IdType="doi">10.1136/jnnp.2003.033258</ArticleId><ArticleId IdType="pmc">PMC1739659</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000F47 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000F47 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:15897497
|texte= Does bilateral stimulation of the subthalamic nucleus aggravate apathy in Parkinson's disease?
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:15897497" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |